Navigation Links
Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
Date:1/22/2008

Speed in Reaching First Clinical Milestone Validates Approach

SAN FRANCISCO, January 22 /PRNewswire/ -- Synosia Therapeutics today announced the successful completion of its first clinical trial, a proof-of-concept study that evaluated new therapeutic options for SYN-111 (rufinamide), a sodium channel blocker. Rufinamide was discovered and developed by Novartis and is currently marketed by Eisai in Europe as a drug to treat a form of epilepsy. This first trial was completed in less than seven months from design to final dosing and less than a year after the rights to rufinamide in mood disorders were obtained from Novartis in an exclusive licensing agreement.

The placebo-controlled, double-blind, three-dose study measured drug effect and pattern of response using quantitative electroencephalography (EEG) in healthy volunteers, who all received each dose plus placebo. After each dose, the subject's brain waves were evaluated over the course of 24 hours, noting quantitative change in each wave and the pattern of the change as an indication of rufinamide activity. The study was conducted in France.

"The data from this study lend support to observations in animal behaviour models and further justify investigation of the effect of rufinamide for mood disorders," said Stephen Bandak, Synosia's Chief Medical Officer. "The study has also helped us select a dose for our Phase 2 trial in general anxiety disorder scheduled to start in the United States later this year."

Rights to SYN111 were obtained by Synosia from Novartis in 2007 in an exclusive worldwide (outside of Japan) licensing agreement to develop and commercialise rufinamide for the treatment of anxiety and other mood disorders. It is estimated that over 62 million people in the United States and the five major European pharmaceutical markets suffer from a form of anxiety. Of those, over nine million suffer from general anxiety disorder.(1, 2)

"Our development approach of
'/>"/>

SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... 19, 2014 Research and Markets ... the "Technology Innovations in Smart Fabrics (Technical ... http://photos.prnewswire.com/prnh/20130307/600769 The ... offers a detailed assessment on technological advancements and ... 1. The Smart Fabrics market ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... jobs Berbee ranks highly in Microsoft partner program ... Wausau police nab suspected wireless hacker ... parent company of SBC Wisconsin, will cut about 10,000 jobs by the ... According to spokesperson Howard Riefs, SBC does not know how many of ...
... we took a look at the PricewaterhouseCoopers quarterly report on venture ... As part of this analysis, we look at VC activity in ... region. , ,This week, lets take a look at VC ... any trends over time. Ready? Here we go! , , ...
... Trying to guess Tommy Thompsons next career move is like attempting ... see through the glass and make an educated guess but ... important disclaimer aside, here are some long-shot predictions about what Wisconsins ... of the U.S. Department of Health and Human Services. For those ...
Cached Biology Technology:Tech Digest: whats moving in the Midwest (11/8/04) 2Though VC investing is down, reloading on new funds is rising 2Though VC investing is down, reloading on new funds is rising 3Could Tommy Thompsons next stop be Transportation, Homeland Security, or the private sector? 2Could Tommy Thompsons next stop be Transportation, Homeland Security, or the private sector? 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... in the park can dramatically change natural ecosystems, according ... University of California, Berkeley. These findings could have important ... parks in the San Francisco Bay Area that allow ... with nearby nature reserves that allow no public access. ...
... Memorial Hospital of Chicago announced today that it has ... its Adult Phenylketonuria (PKU) Outreach Education Project. The ... PKU patients who are no longer being treated at ... education about recent developments in the management and treatment ...
... Researchers from four leading cancer centers have confirmed that ... to predict which lung cancer patients will have the worst ... that would help determine who needs more aggressive treatment. ... Nature Medicine . The researchers looked at ...
Cached Biology News:Outdoor enthusiasts scaring off native carnivores in parks 2Outdoor enthusiasts scaring off native carnivores in parks 3Outdoor enthusiasts scaring off native carnivores in parks 4Children's Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach 2Gene panel predicts lung cancer survival, study finds 2
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
... Competitor Assay Kits are ideal for studying ... PolarScreen GR Competitor Assay Kits contain partially ... one of the following proprietary fluorescent glucocorticoid ... Red (red assay kit), or GS Far ...
... to PRMT5 Arginine methylation is an ... recently been linked to protein activity. At ... been identified in mammalian cells. These enzymes ... functions by methylation of key proteins in ...
... coli Biotinylation Kit, Plasmid is designed for use ... expression kits. (Cat. No. 3 186 148, 3 ... vectors for the easy introduction of a C- ... can be enzymatically mono-biotinylated by E. coli biotin ...
Biology Products: